185 related articles for article (PubMed ID: 16563655)
1. Optimization of combination therapy of arsenic trioxide and fractionated radiotherapy for malignant glioma.
Ning S; Knox SJ
Int J Radiat Oncol Biol Phys; 2006 Jun; 65(2):493-8. PubMed ID: 16563655
[TBL] [Abstract][Full Text] [Related]
2. Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide.
Ning S; Knox SJ
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):197-203. PubMed ID: 15337556
[TBL] [Abstract][Full Text] [Related]
3. Synergistic therapeutic effect of arsenic trioxide and radiotherapy in BALB/C nude mice bearing nasopharyngeal carcinoma xenografts.
Xie LX; Lin XH; Li DR; Chen JY; Hong CQ; Du CW
Exp Oncol; 2007 Mar; 29(1):45-8. PubMed ID: 17431388
[TBL] [Abstract][Full Text] [Related]
4. Study of arsenic trioxide-induced vascular shutdown and enhancement with radiation in solid tumor.
Monzen H; Griffin RJ; Williams BW; Amano M; Ando S; Hasegawa T
Radiat Med; 2004; 22(4):205-11. PubMed ID: 15468939
[TBL] [Abstract][Full Text] [Related]
5. Synergistic interaction with arsenic trioxide and fractionated radiation in locally advanced murine tumor.
Lew YS; Kolozsvary A; Brown SL; Kim JH
Cancer Res; 2002 Aug; 62(15):4202-5. PubMed ID: 12154019
[TBL] [Abstract][Full Text] [Related]
6. Implantable polymers for tirapazamine treatments of experimental intracranial malignant glioma.
Yuan X; Tabassi K; Williams JA
Radiat Oncol Investig; 1999; 7(4):218-30. PubMed ID: 10492162
[TBL] [Abstract][Full Text] [Related]
7. Combined modality treatment using radiation and/or chemotherapy in an athymic nude mouse-human medulloblastoma and glioblastoma xenograft model.
Slagel DE; Feola J; Houchens DP; Ovejera AA
Cancer Res; 1982 Mar; 42(3):812-6. PubMed ID: 7059979
[TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide prevents radiation-enhanced tumor invasiveness and inhibits matrix metalloproteinase-9 through downregulation of nuclear factor kappaB.
Wei LH; Lai KP; Chen CA; Cheng CH; Huang YJ; Chou CH; Kuo ML; Hsieh CY
Oncogene; 2005 Jan; 24(3):390-8. PubMed ID: 15531921
[TBL] [Abstract][Full Text] [Related]
9. NLCQ-1 (NSC 709257) in combination with radiation against human glioma U251 xenografts.
Papadopoulou MV; Bloomer WD; Hollingshead MG
Anticancer Res; 2005; 25(3B):1865-9. PubMed ID: 16158918
[TBL] [Abstract][Full Text] [Related]
10. Human glioblastoma and carcinoma xenograft tumors treated by combined radiation and imatinib (Gleevec).
Oertel S; Krempien R; Lindel K; Zabel A; Milker-Zabel S; Bischof M; Lipson KE; Peschke P; Debus J; Abdollahi A; Huber PE
Strahlenther Onkol; 2006 Jul; 182(7):400-7. PubMed ID: 16826359
[TBL] [Abstract][Full Text] [Related]
11. Protracted exposure radiosensitization of experimental human malignant glioma.
Williams JA; Williams JR; Yuan X; Dillehay LE
Radiat Oncol Investig; 1998; 6(6):255-63. PubMed ID: 9885941
[TBL] [Abstract][Full Text] [Related]
12. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
[TBL] [Abstract][Full Text] [Related]
13. A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells.
Wang W; Adachi M; Zhang R; Zhou J; Zhu D
Pancreas; 2009 May; 38(4):e114-23. PubMed ID: 19342982
[TBL] [Abstract][Full Text] [Related]
14. Preferential action of arsenic trioxide in solid-tumor microenvironment enhances radiation therapy.
Griffin RJ; Williams BW; Park HJ; Song CW
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1516-22. PubMed ID: 15817358
[TBL] [Abstract][Full Text] [Related]
15. Erythropoietin-induced reduction of hypoxia before and during fractionated irradiation contributes to improvement of radioresponse in human glioma xenografts.
Pinel S; Barberi-Heyob M; Cohen-Jonathan E; Merlin JL; Delmas C; Plenat F; Chastagner P
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):250-9. PubMed ID: 15093922
[TBL] [Abstract][Full Text] [Related]
16. Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid.
Campbell RA; Sanchez E; Steinberg JA; Baritaki S; Gordon M; Wang C; Shalitin D; Chen H; Pang S; Bonavida B; Said J; Berenson JR
Br J Haematol; 2007 Aug; 138(4):467-78. PubMed ID: 17587338
[TBL] [Abstract][Full Text] [Related]
17. Response of U87 glioma xenografts treated with concurrent rapamycin and fractionated radiotherapy: possible role for thrombosis.
Weppler SA; Krause M; Zyromska A; Lambin P; Baumann M; Wouters BG
Radiother Oncol; 2007 Jan; 82(1):96-104. PubMed ID: 17161482
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic profile of the human glioma line D-54 MG in athymic mice.
Schold SC; Friedman HS; Bigner DD
Cancer Treat Rep; 1987 Sep; 71(9):849-50. PubMed ID: 3621219
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of arsenic trioxide on retinoblastoma: cell differentiation and apoptosis depending on arsenic trioxide concentration.
Kim JH; Kim JH; Yu YS; Kim DH; Kim CJ; Kim KW
Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1819-23. PubMed ID: 19060284
[TBL] [Abstract][Full Text] [Related]
20. Flavopiridol increases therapeutic ratio of radiotherapy by preferentially enhancing tumor radioresponse.
Mason KA; Hunter NR; Raju U; Ariga H; Husain A; Valdecanas D; Neal R; Ang KK; Milas L
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1181-9. PubMed ID: 15234054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
